– This is a vaccine that has already been used many millions of times, and which has temporary approval for use over 16 years, says assistant health director Espen Nakstad to Dagbladet.
– Then it remains to document that there are no problems with side effects and that it also shows a good effect in those under 16, he says.
– Things change fast
But the way the approval process is set up means that it will not be relevant until after the summer, Nakstad believes.
– It looks like the race that has been put in place for approval, means that this will not be relevant until after the summer. We do not know for sure, but at least it looks like most adults will be offered vaccines towards the summer. In terms of time, it may be that this offer appears after the adults have been vaccinated, says Nakstad.
– But here things change quite quickly in terms of vaccine deliveries as well, he says.
In Europe, Pfizer-Biontech must apply for approval from the European Medicines Agency (EMA) before the Norwegian Medicines Agency agrees to such use.
May take a few months
The process can take one to two months, according to Geir Bukholm, who heads the vaccine program at the National Institute of Public Health (NIPH).
– Then children up to the age of twelve will be a group that we will eventually consider including in the vaccination program, Bukholm told NTB on Wednesday.
The coronary vaccines of Pfizer, Moderna, AstraZeneca and Johnson & Johnson are approved for use in Norway. The AstraZeneca vaccine has been paused following reports of possible serious side effects.
Get the latest news delivered to your inbox
Follow us on social media networks